NCT02753686 - Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy | Biotech Hunter

Enrollment

440

Participants

Timeline

Start Date

March 15, 2016

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions

HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer

Interventions

DRUG

Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant

DRUG

Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy

Trial Locations (25)

T2N 4N2

Novartis Investigative Site, Calgary

V5G 2X6

Novartis Investigative Site, Burnaby

V7L 2L7

Novartis Investigative Site, North Vancouver

V7C 5L9

Novartis Investigative Site, Richmond

V5Z 4E6

Novartis Investigative Site, Vancouver

E1C 6Z8

Novartis Investigative Site, Moncton

E1C 8X3

Novartis Investigative Site, Moncton

N1R 3G2

Novartis Investigative Site, Cambridge

K7L 5P9

Novartis Investigative Site, Kingston

N2G 1G3

Novartis Investigative Site, Kitchener

N6A 5W9

Novartis Investigative Site, London

L3Y 2P9

Novartis Investigative Site, Newmarket

K1H 8L6

Novartis Investigative Site, Ottawa

P6A 2C4

Novartis Investigative Site, Sault Ste. Marie

M2K 1E1

Novartis Investigative Site, Toronto

M4C 3E7

Novartis Investigative Site, Toronto

M5B 1W8

Novartis Investigative Site, Toronto

N8W 2X3

Novartis Investigative Site, Windsor

J4V 2H1

Novartis Investigative Site, Greenfield Park

H3A 1A1

Novartis Investigative Site, Montreal

H3T 1E2

Novartis Investigative Site, Montreal

H4J 1C5

Novartis Investigative Site, Montreal

G1S 4L8

Novartis Investigative Site, Québec

S4T 7T1

Novartis Investigative Site, Regina

S7N 4H4

Novartis Investigative Site, Saskatoon